1. Home
  2. Company
    About Laekna CEO's Message Scientific Advisory Board Milestones Recognition & Awards
  3. R&D
    Therapeutic Areas Pipeline At the Frontier Meet Our Scientists
  4. Partnerships
    Partnerships Business Development
  5. Investors
    Announcements and Circulars Financial Results Corporate Governance Listing Documents
  6. Media
    Press Releases Media Coverage
  7. Careers
    Global Team Career Development Our Values Jobs My Laekna
  8. Sustainability
    ESG Report ESG Performance Highlights Social Responsibility Employee Initiatives

Global

CN EN
At the frontier At the frontier
Home > R&D > At the Frontier
At the frontier

Our R&D Insights

Frontier News Our R&D Insights
Search
  1. Blood
    2014-10-02
    The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

    The PI3K/AKT pathway is constitutively active in hematologic malignancies, providing proliferative and antiapoptotic signals and possibly contributing to drug resistance. 
234
列表空
x
RSS Subscription
To stay informed about Laekna, fill out the form below to subscribe.
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Announcements and Circulars

关注 来凯医药 领英公众号

Follow us on Linkedin

Follow us on Wechat

ir@laekna.com

communication@laekna.com

Copyright © Laekna Therapeutics, All Rights Reserved. 沪ICP备17047795号-2 Privacy Policy 公安备案号：31011502019120sitemap